Eli Lilly to invest $1 bn on India capabilities | 07 October, 2025

Eli Lilly and Co. plans to invest more than $1 billion in India over the next few years to build new contract manufacturing capabilities in the South Asian nation, underscoring the US drug-maker's push to bolster its global supply network.

The Indianapolis-headquartered firm will also establish a new manufacturing and quality centre in Hyderabad, Eli Lilly said in a statement on Monday. This hub will provide advanced technical support and oversight for its contract manufacturing network in India, it said. Recruitment of engineers, chemists, scientists and managers for the Hyderabad hub will start soon.

Eli Lilly, which recently began selling its blockbuster diabetes drug Mounjaro in India, didn’t disclose specific details of $1 billion investment, possible timelines or the therapeutic category in which it wants to do contract manufacturing.

“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, executive vice president and president Lilly International, said in the statement. “This investment reaffirms our confidence in India as a hub for capability building within our global network.”
(Source: Bloomberg)